MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Intellia Therapeutics Inc

Abierto

SectorSalud

8.11 0.12

Resumen

Variación precio

24h

Actual

Mínimo

7.9

Máximo

8.22

Métricas clave

By Trading Economics

Ingresos

6.8M

-129M

Ventas

3.8M

13M

BPA

-1.27

Margen de beneficio

-1,001.227

Empleados

403

EBITDA

8.3M

-134M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+315.65% upside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-352M

820M

Apertura anterior

7.99

Cierre anterior

8.11

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Intellia Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 abr 2025, 09:30 UTC

Principales Noticias

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

12 sept 2024, 17:01 UTC

Principales Noticias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 sept 2024, 11:00 UTC

Principales Noticias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparación entre iguales

Cambio de precio

Intellia Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

315.65% repunte

Estimación a 12 meses

Media 34 USD  315.65%

Máximo 74 USD

Mínimo 9 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Intellia Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

14

Comprar

4

Mantener

1

Vender

Puntuación técnica

By Trading Central

7.26 / 8.31Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.